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Abstract
Objective: Chronic fibrosing liver injury is a major risk factor for hepatocarcinogenesis in humans. Mice with targeted
deletion of Mdr2 (the murine ortholog of MDR3) develop chronic fibrosing liver injury. Hepatocellular carcinoma (HCC)
emerges spontaneously in such mice by 50–60 weeks of age, providing a model of fibrosis-associated hepatocarcinogen-
esis. We used Mdr2
2/2 mice to investigate the hypothesis that activation of the hedgehog (Hh) signaling pathway promotes
development of both liver fibrosis and HCC.
Methods: Hepatic injury and fibrosis, Hh pathway activation, and liver progenitor populations were compared in Mdr2
2/2
mice and age-matched wild type controls. A dose finding experiment with the Hh signaling antagonist GDC-0449 was
performed to optimize Hh pathway inhibition. Mice were then treatedwith GDC-0449 or vehicle for 9 days, and effects on liver
fibrosisand tumorburdenwereassessedbyimmunohistochemistry,qRT-PCR,Western blot,and magneticresonanceimaging.
Results: Unlike controls, Mdr2
2/2 mice consistently expressed Hh ligands and progressively accumulated Hh-responsive
liver myofibroblasts and progenitors with age. Treatment of aged Mdr2-deficient mice with GDC-0449 significantly inhibited
hepatic Hh activity, decreased liver myofibroblasts and progenitors, reduced liver fibrosis, promoted regression of intra-
hepatic HCCs, and decreased the number of metastatic HCC without increasing mortality.
Conclusions: Hh pathway activation promotes liver fibrosis and hepatocarcinogenesis, and inhibiting Hh signaling safely
reverses both processes even when fibrosis and HCC are advanced.
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Introduction
Hepatocellular carcinoma (HCC) is an insidious cancer that
accounts for up to 1 million deaths a year and is the third leading
cause of cancer deaths worldwide [1]. Cirrhosis, a consequence of
progressive liver injury and fibrosis, is the single largest risk factor
for HCC [2]. An altered wound healing response to chronic liver
injury, with resultant dysregulated activation of myofibroblasts and
progenitor cell populations, has been implicated in cirrhosis
pathogenesis and eventual carcinogenesis [3].
Loss-of-function mutations in the hepatocyte canalicular phos-
pholipid flippase MDR3 (ABCB4) have been associated with a
wide range of human biliary diseases including progressive familial
intrahepatic cholestasis type 3 (PFIC3), cholestasis of pregnancy,
drug induced cholestasis and an adult biliary cirrhosis with fea-
tures similar to primary sclerosing cholangitis (PSC) [4,5,6,7].
Mice with a targeted deletion of Mdr2 (the murine ortholog of
MDR3) lack the liver-specific P-glycoprotein that transports
phosphatidylcholine (PC) across the canalicular membrane. The
absence of phospholipids in bile results in progressive sclerosing
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e23943cholangitis with accompanying portal inflammation, ductular
proliferation and portal fibrosis. Liver injury manifests shortly
after birth and hepatocellular carcinomas emerge spontaneously
between 50 to 60 weeks of age [8,9,10,11,12,13,14]. Unlike xeno-
graft models that are widely utilized to examine mechanisms of-
and treatments for- HCC, Mdr2
2/2 mice provide a model that
parallels the natural evolution of HCC on a background of chronic
inflammation, liver injury and fibrosis [15].
Gene expression analyses in Mdr2-deficient mice and hetero-
zygote controls have demonstrated robust and sustained induction
of multiple adaptive mechanisms that control cellular responses
related to oxidative stress, inflammation, lipid metabolism, and
proliferation, prompting speculation that these processes contrib-
ute to hepatocarcinogenesis [16]. Although not formally assessed
by earlier studies of Mdr2-deficient mice, another pathway that
might play a role in fibrosis-associated hepatocarcinogenesis is
Hedgehog (Hh), because Hh signaling has been implicated in both
fibrogenic repair of liver injury and HCC.
The Hh pathway is an evolutionarily conserved signaling
pathway that is activated when Hh ligands (Sonic hedgehog
and Indian hedgehog) bind to Patched (Ptc), a transmembrane
receptor that is expressed on the surface of Hh-responsive cells.
Upon ligand binding, Ptc is inactivated, relieving its repression of
Smoothened (Smo), a trans-membrane protein that mediates Hh
signaling inside the cell. Smo activation culminates in the nuclear
localization of Gli-family transcription factors, Gli1, Gli2, and
Gli3, which, in turn, regulate downstream gene expression. The
pathway is quiescent in normal liver [17,18], but becomes re-
activated as a repair mechanism in chronic liver injury [19,20,
21,22,23]. Hh ligands promote the growth and viability of
myofibroblasts, the accumulation of which leads to abnormal
liver repair, fibrosis and eventual cirrhosis [24,25]. Hh ligands also
serve as viability and proliferative factors for liver epithelial
progenitors, and expansion of this compartment has been linked to
the formation and maintenance of hepatocellular carcinomas [26].
The possibility that Hh pathway activation contributes to
hepatocarcinogenesis is supported by the fact that Sonic hedgehog
(Shh) ligand expression is noted in approximately 60% of human
HCCs, and expression of the Hh-regulated genes, Gli1 and Ptc,
occurs in 50% of human tumors [27,28,29,30].
Based on these observations, we postulated that Hh pathway
activation contributes to the pathogenesis of both liver fibrosis and
fibrosis-associated HCC. To test this hypothesis, we treated aged
Mdr2-deficient mice with the Hh pathway inhibitor, GDC-0449, a
small-molecule inhibitor that binds to Smoothened (SMO). This
agent was selected because of its human safety profile in phase 1
trials, as well as its effectiveness in solid organ tumors like basal cell
carcinoma (BCC) and medulloblastoma [31,32,33]. Our aims
were to determine whether or not mice with advanced liver disease
and HCCs would tolerate Hh pathway inhibition and experience
improvements in liver fibrosis and/or tumor burden.
Methods
Mice
Mdr2
2/2 mice were a gift from Dr. Detlef Schuppan (Beth Israel
Deaconess Medical Center, Boston, MA). Age matched FVB/NJ
wild type mice were obtained from Jackson Laboratory (Bar
Harbor,ME). Allmicewerehoused with a 12-h light-dark cycleand
given water and standard chow ad libitum. At ages, 2, 4, 12, 36 52
and 62-weeks, mice were sacrificed under general anesthesia. Liver
weight and body weight were recorded, serum and liver tissue were
collected. Animal studies were approved by the Institutional Animal
Care and Use Committee as governed by the National Institute of
Health’s ‘‘Guide for the Care and Use of Laboratory Animals’’,
Duke University Animal Welfare Assurance Number A3195-01.
Serum AST/ALT determination
Serum aspartate aminotransferase (AST) and alanine amino-
transferase (ALT) were measured using kits commercially available
from Biotron Diagnostics (66-D and 68-D respectively; Hemet,
CA) according to the manufacturers’ instructions.
Western Blot
Total protein was extracted from snap frozen whole liver tissue
in RIPA buffer. Samples were pooled by age (2–4 samples per age
group) except as noted. Western blot analysis was performed as
previously described. Membranes were probed with the following
primary antibodies: Sonic hedgehog (sc-9024; Santa Cruz
Biotechnology, Santa Cruz, CA), Indian hedgehog (ab39634;
Abcam), b-actin (sc-47778, Santa Cruz Biotechnology), Gli2 (18-
732-292462, Genway, San Diego, CA). All antibodies were diluted
1:1000 and were incubated at 4uC overnight. Western blot images
were acquired using a FluorChem HD2 digital darkroom system
(Cell Biosciences, Santa Clara, California).
Immunohistochemistry
4 mm formalin-fixed, paraffin-embedded samples were dewaxed
and rehydrated. To evaluate tissue architecture, slides were stained
with hematoxylin and eosin (H&E) and Sirius red per standard
protocol. For immunohistochemistry, slides were incubated in 3%
hydrogen peroxide/methanol. Antigen retrieval was performed by
heating in 10 mM sodium citrate buffer or 0.25% pepsin (K19;
Invitrogen, Carlsbad, CA) for 10 minutes. Sections were blocked
(Dako Envision, Carpinteria, CA) and incubated with primary
antibodies overnight at 4uC: glioblastoma-2 (Gli-2; 18-732-292462;
1:2000; Genway, San Diego, CA); cytokeratin 19 (Troma-III;
Hybridoma Bank, Iowa City, IA; 1:500); a-fetoprotein (AFP) (Dako,
1:1000); Indian hedgehog (Abcam; 1:750, Cambridge, MA);
Polymer-HRP anti-rabbit (K4003; Dako) or anti-mouse (K40011;
Dako) or MACH3 mouse AP polymer kit (MP530, Biocare Medical,
Concord, California, USA) were used as secondary antibodies. 3,39-
Diaminobenzidine (DAB) Substrate Chromogen System (K3466;
Dako) and/or Ferangi Blue (Biocare) was employed in the detection
procedure. Omitting primary antibodies from the reactions elimi-
nated staining which demonstrated staining specificity. Images were
acquired on an Olympus IX71 (Tokyo, Japan) inverted microscope
using the DP2-BSW (Olympus) image acquisition software system.
Quantitative Real-Time Reverse Transcription PCR
RNA was isolated from whole liver, as well as from resected
tumor specimens had standard TriZol extraction as has been
previously described [24]. A table of primers has been included in
the Supplementary Materials.
Morphometry
Formalin-fixed liver and tumor sections were stained for CD44
and osteopontin as described above, and were quantified by
morphometric analysis with MetaView software (Universal
Imaging, Downington, PA). A minimum of 5 randomly selected
106or 206fields/section were evaluated for each mouse.
Quantitative Immunohistochemical Analysis
Formalin-fixed liver and tumor sections were costained for Gli2
and CK19. A minimum of 5 ductular regions, 206 fields per
section, were evaluated for each mouse by counting the number of
cells co-labelled.
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The hydroxyproline content in whole liver specimens was
quantified colorimetrically as previously reported [34].
GDC-0449 treatment
In the initial, dose-finding cohort of animals, 16 Mdr2
2/2 mice
(age 57–68 weeks) were assigned to treatment with vehicle control
(DMSO, n=5), 20 mg/kg GDC-0449 (n=5), or 40 mg/kg GDC-
0449 (n=6). Male-female ratios were balanced between the groups.
GDC-0449 (Selleck Chemicals, Houston, TX) was freshly constituted
daily in DMSO. All mice were given a daily intraperitoneal injection
for9 days. On day10, animals were sacrificed.Sampleswere collected
as above. A second cohort of 20 Mdr2
2/2 mice (age 51–59 weeks of
age) were subjected to whole body magnetic resonance imaging to
assess tumor burden and then pairs of mice with comparable tumor
burdens were assigned to treatment with either DMSO (control,
n=10) or 40 mg/kg GDC-0449 (n=10). Drugs were delivered as
described above; MRI scanning was repeated after the 9
th day of
treatment; mice were sacrificed for necropsy and tissue harvest.
Pathology
H&E and sirius red staining of liver sections was evaluated by a
board-certified pathologist. Representative sections of tumor and
non-tumortissuewereexamined.Tumortissuewasdefined asgrossly
visible nodules that were at least 10 mm in size and resectable.
Abdominal magnetic resonance imaging
Animals were assigned a blinding code, which was maintained
during magnetic resonance (MR) data acquisition and analysis. MR
mouse liver imaging was performed on a 7T Bruker Biospec 70/30
horizontal bore system (Billerica, MA). Animals were lightly
anesthetized under isofluorane with continuous monitoring and
maintenance of physiological parameters throughout the imaging
session (,60 min for each animal). Axial and coronal 2D T2-weighted
fast spin echo images (TURBO-RARE, TE/TR=11/4200 ms with
1 mm slice thick, matrix=2566256 and FOV of 2.4 cm62.4 cm, 5
averages, 0.0 mm interslice gap) images were first obtained for
screening purposes and supplemental anatomic information. For
directed tumor volumetric analysis, 64 contiguous 500 mMt h i c k3 D
FSE proton density images biased towards T1 weighting (TURBO-
RARE, TE/TR=9/1500 ms, matrix=2566256664 and FOV
2.2 cm62.2 cm62.2 cm, 25 minutes duration) were acquired. All
imaging sequences were performed using respiratory gating.
Volumetric analysis from MR data sets was performed in Osirix
software, an open source image processing application developed and
maintained by Pixmeo (Geneva, SUI). Liver tumors were manually
segmented in each animal by a board-certified radiologist (blinded to
treatment) post-treatment. Selected areas were reviewed for consis-
tency on coronal and sagittal representations, and cross-correlated
with axial 2D FSE images. For volumetry, two separate volume
measurements were obtained for each lesion, with the average
volume then taken. Interrater reliability (kappa value) was=0.97. T1
and T2-weighted scanning sequences were performed.
Statistical analyses
Results expressed as mean6SD. Significance established using
the Student’s t-test. Differences were considered significant when
p,0.05.
Results
Progressive accumulation of Hh-responsive cells in
Mdr2
2/2 mice
Various forms of acute and chronic liver injury induce hepatic
expression of Hh ligands and activation of Hh responsive cells.
Serum levels of AST and ALT were consistently higher in
Mdr2
2/2 mice than age-matched controls (Figure S1), confirm-
ing that the knockout mice had chronic liver injury. Thus, we
surveyed livers from Mdr2
2/2 mice for Hh pathway activation.
Compared to liver protein lysates from wild type controls, lysates
from Mdr2
2/2 mice demonstrated an increase in Sonic hedgehog
(Shh) and Indian hedgehog (Ihh) by Western blot analysis. This
was apparent at the first time point examined (2 weeks after birth)
and maintained throughout the lifespan of the animals (up to 64
weeks of age) (Figure 1A). Immunohistochemistry for the Hh-
regulated transcription factor, Gli2, demonstrated progressive,
age-related accumulation of cells with nuclear Gli2 staining in
Mdr2
2/2 mice. Such Gli2-positive cells included stromal cells, as
well as hepatocytic and ductular cells (Figure 1B–C). Together,
these data suggest that the Hh pathway is activated in chronically
injured livers of Mdr2-deficient mice, resulting in progressive
expansion of various Hh-responsive cell populations.
Treatment of Mdr2
2/2 mice with the Smoothened
inhibitor, GDC-0449, is safe and decreases Hedgehog
pathway signaling
To determine the appropriate dose of GDC-0449, a pilot study
was done with 16 aged (57–68 week old) Mdr2
2/2 mice. Animals
weregiven a daily intraperitoneal injection of20 mg/kgGDC-0449
(n=5), 40 mg/kg GDC-0449 (n=6), or DMSO vehicle control
(n=5) for 9 days and then sacrificed. There was no statistical
difference in mortality between the control and high dose (40 mg/
kg) GDC-0449 groups. At sacrifice, liver/body weight ratios of mice
in the three groups were also similar, suggesting that a relatively
short course of systemic treatment with GDC-0449 at 40 mg/kg is
well tolerated by mice with advanced liver disease and HCC
(Figures S2A–B). Western blot analysis of liver lysates from this
cohort of animals demonstratedthat GDC-0449 treatment caused a
decrease in Shh ligand levels at the higher dose, and Gli2 expression
attenuation at both doses (Figure S2C).
Hedgehog signaling inhibition with GDC-0449 abrogates
effects of Hh signaling on target gene expression
Based on the data acquired in our dose-finding study, a second
cohort of Mdr2
2/2 mice (51–59 weeks of age) were assigned to
treatment with vehicle (DMSO; n=10) or 40 mg/kg GDC-0449
(n=10) via daily i.p injection for 9 days. Overall survival between
the two groups inthe second cohortwas equal, withno deathsin the
DMSO treatment group and 1 death in the GDC-0449 treatment
group secondary to iatrogenic injury. Both the liver parenchyma
and tumors of treated mice showed decreased expression of the Hh
pathway target Gli2 (Figures 2A–B). Real-time PCR analysis of
resected tumors revealed that GDC-0449 treatment released the
inhibitory effects of Hh signaling on PPARa ˜, causing a significant
increase in its gene expression (Figure 2C). Treatment with GDC-
0449 also caused a significant decrease in expression of Gli1,
another Hh target gene (Figure 2D).
Hedgehog signaling inhibition with GDC-0449 reduces
liver fibrosis
Mdr2
2/2 micedemonstrated progressive age-relatedincreases in
hepatic expression of alpha-smooth muscle actin (a-sma), a marker
of myofibroblastic hepatic stellate cells (Figure 3A, top panel).
This was accompanied by enhanced expression of pro-fibrogenic
factors, such as transforming growth factor TGF-b and platelet
derived growth factor PDGF-b (Figures S3A–B), and progressive
fibrosis, as evidenced by Sirius red staining (Figure 3A, bottom
panel) and quantification of the hepatic hydroxyproline content
Hedgehog Pathway Inhibition in Liver Cancer Model
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expressing myofibroblastic cells, hepatic expression of TGF-b and
PDGF-b, Sirius red staining, and hydroxyproline content, demon-
strating that Hh pathway inhibition reduced liver fibrosis
(Figures 3C–D and Figures S3C–D).
Hedgehog signaling inhibition with GDC-0449 decreases
accumulation of liver progenitor cells
In response to injury, progenitor populations in the liver
proliferate. Hence, immunohistochemical analysis for progenitor
markers, such as cytokeratin-19 (CK-19) and a-fetoprotein (AFP),
showed age-related increases in Mdr2
2/2 mice (Figure 4A). Co-
staining for CK19 and Gli2 confirmed that the progenitor
population was Hh responsive (Figure 4B). Upon treatment with
GDC-0449, progenitor markers decreased (Figure 4C), indicat-
ing that Hh signaling was required to maintain progenitor
populations during tumorigenesis, and that Hh inhibition was
sufficient to shrink the size of progenitor populations even in mice
with advanced HCC.
Decreasing Hedgehog signaling reduces expression of
osteopontin and prevents accumulation of osteopontin-
responsive (CD44-positive) cells
Stem/progenitor cell populations for many types of cancer,
including HCC, are thought to be enriched with cells that express
CD44, a receptor for the stem cell growth factor, osteopontin
[35,36]. Osteopontin expression is regulated by Hh signaling
[37]. Therefore, we examined the effects of GDC-0449 on
osteopontin and its receptor, CD44. Immunohistochemistry and
quantitative morphometry demonstrated that inhibition of the
Hh pathway with GDC-0449 significantly decreased osteopontin
staining within primary liver tumors (Figure 5A). Similar
treatment-related decreases in CD44+ tumor cells were also
noted (Figure 5B). Gene expression analysis showed that
expression of both osteopontin and CD44 mRNAs also tended
to decrease in GDC-0449-treated mice (Figure 5C). Together,
these results suggest that Hh signaling may regulate putative liver
cancer stem/progenitor cells by modulating availability of
osteopontin.
Figure 1. Increased hepatic Hedgehog (Hh) pathway activity in Mdr2
2/2 mice. A. Western blot analysis for Sonic Hedgehog (SHh) and
Indian Hedgehog (IHh) in whole liver extracts pooled from young Mdr2
2/2 mice (2–16 weeks old), old (36–64 weeks old) Mdr2
2/2 mice and age-
matched controls (n=3–5 mice/group/time point). A representative Western blot demonstrating results from young mice is shown. Mean6SEM data
from older mice are graphed. B. Representative liver sections stained to demonstrate Gli2 from young (4 wk old), middle aged (36 wk old) and old
(52 wk old) Mdr2
2/2 mice. Little Gli2 expression was noted in wildtype mice at any age, so results from a representative 36 wk old wild type mouse is
shown. (106) C. Quantitative Gli2 immunohistochemical data. The number of nuclear Gli2(+) cells was counted in at least 5 high power fields (HPF)
per liver section in Mdr2
2/2 mice and wild type controls at 4, 36 and 64 weeks of age (n=3–4 mice/group/time point) and mean6SEM are graphed.
*p,0.05, **p,0.01 in Mdr2
2/2 groups vs. respective controls.
doi:10.1371/journal.pone.0023943.g001
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following GDC-0449 treatment
To evaluate the potential impact of changes in matrix and
progenitor cells on HCC, pre- and post-treatment tumor volumes
were analyzed using magnetic resonance imaging (Figures 6A–B).
An analysis of tumors in mice without overt metastasis demonstrat-
ed that tumor volumes decreased in mice that received a 9 day
course of GDC-0449-treatment, while vehicle-treated animals
evidenced persistent tumor growth (Figure 6C; 26.7%+/
211.7% vs 22.7% +/29.1%, p=0.03). This data correlated with
Figure 2. Hedgehog (Hh) inhibitor, GDC-0449, abrogates effects of Hh signaling within liver parenchyma and HCC nodules. A. Liver
sections stained for Gli2 from representative DMSO- and GDC-0449- treated mice (406). Quantitative Gli2 immunohistochemistry data in non-tumor
livers of mice treated with DMSO or GDC-0449 (n=9–10/group) are graphed as mean6SEM (**p,0.01. The number of ductular cells with Gli2 positive
staining were counted in each portal tract/section under 406magnification. B. Tumor sections from the same mice were also stained to demonstrate
Gli2. Results from representative DMSO- and GDC-0449-treated mice are displayed. Quantitative Gli2 immunohistochemistry data were generated by
counting nuclear Gli2 positive ductular and hepatocytic cells in tumor sections under 406magnification. Results are graphed as mean6SEM Gli2-
positive cells/406high power field (**p,0.01) C–D Quantitative reverse transcription-PCR (qRT-PCR) analysis of whole liver RNA from DMSO-(open
bar) and GDC-0449 (black bar) treated mice. C. PPAR-c, a gene that is normally repressed by Hh signaling. D. Gli1, a gene that is induced by Hh
signaling. Mean6SEM are graphed (**p,0.01).
doi:10.1371/journal.pone.0023943.g002
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liver tumor nodules, compared to 80% of the DMSO mice
(Table 1). Furthermore, both MRI and necropsies showed a
decreased number of metastasis in GDC-0449-treated mice
compared to vehicle-treated controls (Table 1). Histological
analysis of H&E-stained liver sections was also performed on all
animals from both cohorts. If tumor nodules were not grossly visible
or greater than 10 mm in size, the samples were excluded from
analysis. Microscopic tumor nodules in GDC-0449 treated animals
demonstrated increased rates of hemorrhagic infarct (20% vs 0%;
Figure 6D, top panel), microvesicular steatosis (40% vs 0%,
Figure 6D, middle panel), acidophilic necrosis and degenerative
cytoplasmic changes (70% vs 40%, Figure 6D, bottom panel)i n
comparison to tumors from vehicle treated animals. Thus, findings
on MRI, necropsy, and liver histology were consistent and
demonstrated that Hh pathway inhibition caused significant
regression of primary and metastatic HCC.
Discussion
We studied Mdr2
2/2 mice to determine whether or not
activation of the Hh pathway contributes to hepatocarcinogenesis
Figure 3. GDC-0449 treatment reduces fibrosis in Mdr2
2/2 mice. A. Immunohistochemical staining for a-SMA (top panel) and Sirius red
(bottom panel) in sections of non-tumor liver from representative age-matched Mdr2
2/2 and wildtype mice (106). B. Pooled Hepatic hydroxyproline
content of 2–52 wk-old wildtype (WT) and age-matched Mdr2
2/2 mice (n=3–5/group). Results in Mdr2
2/2 mice were normalized to that of age-
matched WT mice and graphed as fold change. Data are displayed as mean +/2 SD (*p,0.05) C. Non-tumor liver sections stained for a-SMA (top
panel, 206) and Sirius red (bottom panel, 106) in representative DMSO- and GDC- treated Mdr2
2/2 mice. D. Heptic hydroxyproline content of
DMSO- and GDC- treated mice (n=9/group). Results in GDC-0449-treated mice were normalized to that of DMSO vehicle-treated mice and graphed
as fold change. Data are displayed as Mean +/2 SEM (*p,0.05).
doi:10.1371/journal.pone.0023943.g003
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PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e23943Figure 4. Effects of Mdr2 deficiency and Hedgehog (Hh) inhibition on hepatic progenitor populations. A. Immunohistochemical
staining of liver sections from representative, age-matched Mdr2
2/2 and wildtype mice for progenitor markers, cytokeratin-19 (CK-19) (top panels)
and a -fetoprotein (AFP) (bottom panels) (206). B. Representative micrograph of a portal triad in liver of an Mdr2
2/2 mouse, demonstrating co-
localization of CK-19 (blue) and Gli2 (brown) in the ductular compartment (406). C. Quantitative Gli2 and CK19 immunohistochemistry in DMSO- and
GDC-0449-treated Mdr2
2/2 mice (n=9–10/group). The number of Gli2 and CK19 double-positive ductular-appearing cells were counted within
tumors under 206magnification. Mean6SEM double(+) cells t per high power field (HPF) are graphed (* p,0.05) D. QRT-PCR analysis of AFP in
tumor RNA from mice treated with DMSO (open bar) or GDC-0449 (closed bar) Results in the GDC-0449-treated mice were normalized to that of the
mice treated with DMSO vehicle and graphed as Mean6SEM (*p,0.05).
doi:10.1371/journal.pone.0023943.g004
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phospholipid flippase that is required for normal bile formation,
and consequently exhibit liver injury and ductular proliferation
from a young age. All afflicted mice eventually develop significant
liver fibrosis and metastatic HCC. Our results demonstrate that
this pathology is accompanied by progressive activation of the Hh
pathway. Introduction of a specific inhibitor of the key Hh
signaling intermediate, Smoothened, reduced pathway activity
and proved that sustained Hh signaling was required to maintain
the expanded populations of liver myofibroblasts and progenitors
that had accumulated in the damaged livers. Moreover, treating
aged Mdr2-deficient mice (which already had advanced liver
fibrosis and HCC) with the Hh pathway inhibitor significantly
reduced liver fibrosis and tumor burden, demonstrating for the
first time that inhibiting Hh signaling has clinically-relevant,
therapeutic value for both liver fibrosis and HCC. Even more
exciting is evidence that the prohibitive effect on hepatic tumor
growth in vivo pertains to both intra-hepatic HCC and distant
metastasis.
In addition, our results provide insight into some of the
underlying mechanisms involved. Hepatic production of Hh
ligands was increased in mice that developed progressive liver
fibrosis and invasive HCC. These mice also demonstrated
consistently higher serum aminotransferase levels, in keeping with
other evidence that Mdr2 deficiency provokes chronic hepatocyte
injury [38,39]. Various stressors that reduce hepatocyte viability
have been shown to induce production and release of Hh ligands
by wounded hepatocytes [40,41]. Thus, hepatocyte injury is likely
one of the factors that increases Hh ligand generation in mdr2-
deficient livers. Myofibroblastic cells and ductular-type progenitors
that progressively accumulate in chronically injured livers also
produce Hh ligands, as well as other factors, such as PDGF-b, that
Figure 5. Inhibition of Hh signaling decreases osteopontin and osteopontin-responsive (CD44) positive cells in tumors and peri-
tumoral tissues of aged Mdr2
2/2 mice. A. Tumor sections from representative DMSO- and GDC-0449 treated Mdr2
2/2 mice were stained to
demonstrate osteopontin (OPN) Representative sections are displayed (Right panel). OPN staining was quantified by morphometric analysis of at least
5 HPF per tumor section using 206magnification (n=5 mice/group). Results in the GDC-0449-treated group were normalized to that of the group
treated with DMSO vehicle and graphed as fold change. Data are displayed as Mean6SEM (**p,0.01). B. Immunohistochemical staining for the
osteopontin receptor, CD44, in peri-tumoral tissues of representative DMSO- and GDC-0449- treated Mdr2
2/2 mice. (Right panel) CD44 staining was
quantified by morphometric analysis as described in A. Results in GDC-0449-treated mice were normalized to those of vehicle-treated controls and
graphed as Mean6SEM (**p,0.01). C. QRT-PCR analysis of liver tumor RNA from DMSO- (open bar) and GDC-0449- (closed bar) treated Mdr2
2/2
mice for OPN (left) and CD44 (right). After normalization to results in the DMSO-treated group, Mean6SEM were graphed (*p,0.05).
doi:10.1371/journal.pone.0023943.g005
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Relative to age/gender matched healthy control mice, aged mdr2-
deficient mice with ductular reactions and liver fibrosis demon-
strated higher hepatic mRNA levels of PDGF-b, suggesting a
mechanism by which the fibrogenic repair response itself might
perpetuate excessive hepatic accumulation of Hh ligands. The
latter concept is supported by evidence that inhibiting Hh
signaling with GDC-0449 reduced accumulation of myofibroblasts
and ductular-type progenitors, decreased expression of PDGF-b,
and suppressed hepatic expression Hh ligands in mice that
remained at risk for hepatocyte injury due to genetic deficiency of
Mdr2.
Chronic over-production of Hh ligands has important patho-
biological implications because mice that generated increased Hh
ligands also demonstrated excessive activation of the Hh pathway
in their livers. This was evidenced by larger numbers of cells with
nuclear staining for the Hh-regulated transcription factor, Gli2,
and enhanced expression of various Hh-target genes, including
Gli1 and osteopontin. In such animals, we showed that treatment
with a highly specific antagonist of Smoothened was able to
Figure 6. Hh pathway inhibition decreases in liver tumor volume by magnetic resonance imaging (MRI) and induces histologic
features of tumor involution. A. Representative cross-sectional image of intrahepatic tumor as identified by contrast-enhanced MRI following
GDC-0449 treatment. B. Representative MRI images of sagittal, coronal, and oblique perspectives used for volumetric analysis. C. Change in tumor
volume were quantified by computerize generated volumetric measurements and graphed as Mean6SD (*p,0.05). D. Micrographs of representative
histologic changes induced by, GDC-0449, treatment. Top panel shows tumor necrosis; middle panel demonstrates fatty degeneration; bottom panel
show vacuolated tumor cells with pyknotic nuclei.
doi:10.1371/journal.pone.0023943.g006
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that activation of Smoothened in Hh-responsive cells promotes
nuclear localization of Gli2, and consequent induction of Gli1 and
osteopontin transcription [43,44]. Osteopontin, in turn, has been
shown to promote myofibroblast accumulation and liver fibrosis in
mice [37,45]. It also acts via its receptor, CD44, to enhance the
viability and growth of certain types of liver progenitors, including
liver cancer stem/progenitor cells [35,36,46,47]. Hence, the Hh
pathway might be modulating both liver fibrosis and HCC
outgrowth by regulating the autocrine/paracrine availability of
osteopontin.
Myofibroblasts and ductular progenitor cells are also important
sources of other pro-fibrogenic factors (e.g., PDGF-b and TGF-b)
that are capable of activating Gli2 via mechanisms that do not
require Smoothened [48,49,50]. We observed increased hepatic
expression of both PDGF-b and TGF-b in Mdr2-deficient mice.
This suggests that Smoothened-independent mechanisms that re-
enforce the effects of the canonical Hh pathway may evolve during
fibrogenic repair. In mdr2-deficient mice, however, GDC-0449
significantly reduced expression of TGF-b and tended to suppress
expression of PDGFb, demonstrating that canonical Hh signaling
with resultant Smoothened activation is ultimately required to fully
engage noncanonical pathways that rely on interaction of TGF-b
and PDGF-b with their respective receptors to activate Gli2 in
injured, fibrotic livers.
Finally, the fact that liver fibrosis/cirrhosis is a major risk factor
for the development of HCC should not be misconstrued to imply
that fibrosis per se causes cancer. It is conceivable that fibrosis and
HCC each result from some adaptive response that occurs during
chronic liver injury. Our results demonstrate that injury-related
activation of the Hh pathway typifies an adaptive response that is
both pro-fibrogenic and pro-carcinogenic. This discovery, in turn,
provides novel evidence that helps to explain why fibrosis and
HCC often develop in the same livers. As such, it has immediate
clinical relevance to the many cirrhotic patients with HCC.
Additional research will be required, however to delineate the
precise down-stream mechanism(s) involved and to determine
which (if any) of those subsequent fibrogenic and carcinogenic
processes are inter-dependent, and which are totally independent
of each other.
Proof that inhibition of Hh signaling substantially reduced the
hepatic content of myofibroblasts and progenitors suggests that
these cell types promote and/or maintain the outgrowth of
malignant hepatocytes. This finding, in turn, provides a starting
point for further research. Indeed, others have reported that
Smoothened antagonists lead to the involution of pancreatic
cancers by influencing tumor angiogenesis [51]. Myofibroblasts
are known to be an important source of vascular growth factors,
such as VEGF [52,53,54], and we found increased hepatic
expression of VEGF and its receptor, VEGFR1, in the diseased
livers of Mdr2-deficient mice compared to the healthy livers of
age/gender-matched controls (data not shown). Hence, it is
possible that myofibroblast depletion exerted a negative impact on
the hepatic vasculature that ultimately resulted in HCC involution.
This concept is supported by evidence that GDC-0449 tended to
suppress hepatic expression of VEGF/VEGFR1 (data not shown)
and increased necrosis in the HCC of GDC-0449-treated mice.
Hh signaling is also known to maintain various progenitor
populations [55,56,57]. Previously, we reported that Hh ligands
function as autocrine and paracrine survival signals for liver
progenitors and showed that liver myofibroblasts are an important
paracrine source of Hh ligands that serve this purpose
[40,42,58,59,60]. Liver progenitors, in turn, generate Hh ligands
that provide paracrine signals that re-enforce the growth of liver
myofibroblasts [61,62]. Given this background, it is not surprising
that blocking Hh signaling with a Smoothened antagonist resulted
in the mutual depletion of both cell types. To our knowledge,
however, by demonstrating marked treatment-related decreases in
CD44, cytokeratin-19, and a-fetoprotein within HCC tumors, the
current data provide the first evidence that Smoothened
antagonists reduce populations of cells that exhibit features of
tumor stem/progenitor cells. Further investigation is required to
ascertain how aberrant Hedgehog signaling promotes these cancer
stem cell compartments.
In conclusion, our findings in the Mdr2
2/2 mouse model of
progressive liver fibrosis and spontaneous hepatocarcinogenesis
demonstrate that increased production of Hh ligands and
progressive accumulation of Hh-responsive cell types, such as
myofibroblasts and liver progenitor cells, precede the emergence of
HCC, and persist after the development of HCC. Despite
advanced liver fibrosis and HCC, a short course of treatment
with a highly-specific and clinically available Hh signaling
inhibitor is well-tolerated and demonstrates appreciable anti-
tumor effects. Thus, Hh pathway inhibition with GDC-0449
merits evaluation as a potential treatment for HCC arising in
cirrhotic patients, providing a novel treatment option for an
emerging disease with a poor prognosis and limited therapeutics.
Supporting Information
Figure S1 Evidence of ongoing liver injury in Mdr2
2/2
mice. AST and ALT measurements from Mdr2
2/2 mice and
their age-matched wild type counterparts at various time points.
Each data point represents n=2–7 animals and Mean6SD is
graphed. (*p,0.05 vs the age-matched wild-type control).
(TIFF)
Figure S2 Systemic treatment of GDC-0449 treatment is
well tolerated in Mdr2
2/2 mice with advanced liver
disease and HCC. A. Daily body weight measurements were
obtained for all animals in each of the three treatment groups and
graphed over time. Data expressed as Mean6SD. B. Liver to
body weight ratios of animals in each of the three treatment
groups. Data expressed as Mean6SD. C. Western blot analysis for
Shh, Gli1, Gli2 and actin (loading control) in whole liver extracts
from Mdr22/2 mice treated with vehicle, 20 mg/kg GDC-0449,
and 40 mg/kg GDC-0449. Liver extracts from each treated mouse
were loaded individually.
(TIFF)
Figure S3 Increased hepatic expression of TGFb and
PDGFb in Mdr2
2/2 mice is reversed by GDC-0449
treatment. Whole liver RNA was isolated from Mdr2
2/2 mice
and age/gender-matched wild type controls (WT) (n=3 mice/
group) and QRT PCR was done to compare expression of (A)
TGFb and (B) PDGFb. Similar approaches were used to assess the
Table 1. Effect of GDC-0449 treatment on intrahepatic HCC
and HCC metastases.
Surgical Resection MRI Imaging
Vehicle Treatment Vehicle Treatment
Intrahepatic
Tumor Nodules
80% 56% 78% 50%
Metastases 20% 0% 50% 20%
doi:10.1371/journal.pone.0023943.t001
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inhibitor GDC-0449 or vehicle (DMSO) on expression of (C)
TGFb and (D) PDGFb in Mdr2
2/2 mice (n=5 mice/group).
Gene expression was normalized to expression of S9 in the same
samples; mean +/2 SEM values were calculated; values in the
experimental groups were graphed relative those in the respective
controls. P values are shown.
(TIF)
Table S1
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